Asunto(s)
Manejo de la Enfermedad , Neoplasias/mortalidad , Neoplasias/enfermería , Cuidados Paliativos/normas , Pediatría/normas , Calidad de la Atención de Salud/normas , Cuidado Terminal/normas , Adolescente , Adulto , Niño , Preescolar , Estudios de Cohortes , Femenino , Predicción , Humanos , Lactante , Recién Nacido , Masculino , Cuidados Paliativos/tendencias , Pediatría/tendencias , Calidad de la Atención de Salud/tendencias , Cuidado Terminal/tendenciasRESUMEN
An 11-year-old Turkish girl from a non-consanguineous family was suffering from joint pain, fever, hepatosplenomegaly, and respiratory insufficiency. Laboratory abnormalities were thrombocytopenia, elevated levels of serum transaminases, lactate dehydrogenase, and C-reactive protein (up to 193 mg / l), a hyperferritinaemia of 8030 ng/ml, and an increased sCD25. The tentative diagnosis of macrophage activation syndrome (MAS) was confirmed by the detection of a histiocytosis with haemophagocytosis in the bone marrow. Treatment with dexamethasone, cyclosporine A, and VP16 was successful. However, the diagnosis of MAS on the background of a systemic juvenile idiopathic arthritis was questionable because of recurrent, spontaneously remitting fever phases of 5 to 7 days duration without an obvious infectious aetiology. A positive family history of febrile episodes in three consecutive generations raised the suspicion of a dominantly inherited disease. Genetic studies revealed a likely pathogenetically relevant E56D/p.Glu85Asp mutation in exon 3 of the TNFRSF1A gene. Alterations of the MEFV gene, in contrast, were not found. To our knowledge, this is the first case of a macrophage activation syndrome as the initial manifestation of TRAPS. Similar case reports in patients with the far more common familial Mediterranean fever (FMF) have been published already.
Asunto(s)
Enfermedades Autoinflamatorias Hereditarias/inmunología , Síndrome de Activación Macrofágica/inmunología , Niño , Ciclosporina/uso terapéutico , Análisis Mutacional de ADN , Dexametasona/uso terapéutico , Quimioterapia Combinada , Etopósido/uso terapéutico , Femenino , Fiebre , Predisposición Genética a la Enfermedad , Enfermedades Autoinflamatorias Hereditarias/complicaciones , Enfermedades Autoinflamatorias Hereditarias/diagnóstico , Herencia , Humanos , Inmunosupresores/uso terapéutico , Síndrome de Activación Macrofágica/diagnóstico , Síndrome de Activación Macrofágica/genética , Mutación , Linaje , Fenotipo , Receptores Tipo I de Factores de Necrosis Tumoral/genética , Resultado del TratamientoRESUMEN
On-site tests based on immunoassay techniques are widely used for toxicologic screening analysis in patients with suspected poisoning. However, such assays usually have been validated using urine samples with known concentrations of the investigated substances. In the present investigation, on-site screening results were evaluated in a clinical setting. This was a retrospective study of patients with suspected poisoning from January to December 2003 in the emergency department of a tertiary urban hospital. Urine samples were analyzed using the Triage 8 panel and gas chromatography-mass spectrometry (GC-MS). A total of 111 patients were included (54 female, 57 male; average age 37.8 +/- 19.7 years). A total of 3.8% of the patients showed no symptoms, 45.2% minor, 24.0% moderate, and 26.9% serious symptoms. In 50 patients (45.0%), Triage 8 results corresponded well with GC-MS results. In 17 patients (15.3%), the Triage 8 results were confirmed by GC-MS, but additional substances were determined that could not be detected by the Triage 8 panel. A completely negative Triage 8 screening result was obtained in 23 patients (20.7%) who showed toxicologically relevant findings in GC-MS. In 21 patients (18.9%), Triage 8 results could not be confirmed by GC-MS. The analysis of the results in view of the patients' medical histories revealed that in 20 patients (18.0%), no relevant toxic substance could be detected. Additionally, 8 patients (7.2%) showed intoxication with alcohol, which could not be detected by the presently applied toxicologic screening investigations. On-site screening results in suspected poisoning were not very helpful in the present study because practically every second patient ingested substances that were not detectable by the Triage 8 device. In addition, every fifth result was not in line with GC-MS findings. On-site test findings should be interpreted very carefully, and in critical cases, a GC-MS screening should be performed.